The poster will be accessible as a PDF after it is offered on Array’s website. Related StoriesNew Cleveland Clinic study shows bariatric surgery is safe choice for managing type 2 diabetes in over weight or mildly obese patientsBetalin launches brand-new EMP technology that could transform diabetes treatmentType 2 diabetes drug significantly reduces hospitalizations, death from center failureThe data presented are consistent with the positive top-series outcomes announced in August 2009 showing that ARRY-403 met its principal and secondary endpoints of security, pharmacokinetics and glucose control in a Phase 1 SAD study. The scholarly research included seven dose cohorts, with a complete of 41 sufferers with type 2 diabetes who received either placebo or a single dose of ARRY-403 which range from 25 mg to 400 mg.– 6:00 p.m. ‘An international, double-blind, randomized, placebo-controlled stage III trial of cabozantinib in medullary thyroid carcinoma patients with documented RECIST progression at baseline’ Dr.m. – 1:00 p.m. Related StoriesMD Anderson study reveals why chemotherapy drugs not effective for many pancreatic cancer patientsOvarian malignancy patients with a history of oral contraceptive make use of possess better outcomesNew RNA check of blood platelets can be used to detect location of cancer ‘Cabozantinib in chemotherapy-pretreated metastatic castration resistant prostate cancers : Results from a stage II nonrandomized expansion cohort ‘ Dr.